eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2005
vol. 1
 
Share:
Share:
more
 
 

CASE REPORT
Leigh disease: 9 years follow up of a Polish family harboring T8993C mitochondrial DNA mutation

Bartłomiej Kisiel
,
Lech Korniszewski
,
Łukasz A. Małek

Arch Med Sci 2005; 1, 1: 59-62
Online publish date: 2005/05/06
Article file
- Leigh.pdf  [0.06 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 
Submitted: 12 February 2005
Accepted: 13 March 2005


Corresponding author:
Łukasz A. Małek
Kazury 1/13
02-795 Warsaw, Poland
Phone: +48 501 034 090
Phone/fax: +48 22 648 32 23
E-mail: lamalek@amwaw.edu.pl




Introduction
Leigh syndrome (LD) or subacute necrotizing encephalopathy (SNE) was first described in 1951 and belongs to a growing number of diseases called mitochondrial myopathies [1, 2]. There are 3 major causes of Leigh syndrome, each transmitted by a different mode of inheritance: X-linked recessive, autosomal recessive and maternal [1, 3, 4]. All of the causes lead to the impairment of the mitochondrial function. The studied family harbors a common T8993C Leigh mutation in the ATP6 subunit of the ATP synthase (complex V of the electron transporting chain). Some of the complex V subunits as well as some subunits of all the other ETC complexes except the second one are encoded by 16,5 kb mitochondrial DNA (mtDNA). Coexistence of normal and mutated DNA copies within one cell is known as heteroplasmy, but its degree (percentage of mutated mtDNA) only partially correlates with severity of symptoms. What is more, all three general types of inheritance may present different phenotypes. The onset symptoms of Leigh disease usually include neurogenic muscle weakness, but classification of LS symptoms varies from case to case which is provoked by a small number of patients studied and published. Most common clinical manifestations found in literature are presented in Table I [1, 5-7].

Subjects and methods
Subjects

The study included three patients: a 50-year-old white woman (case 1) and her 18-year-old twin daughters (cases 2 and 3) all harboring T8993C mutation in ATP6ase gene of mtDNA.

Quality of life questionnaire (QOL)
To assess the quality of life a questionnaire specific for Leigh disease was constructed. It consisted of two parts, part A concentrating on the physical state and part B describing the psychological condition of the patients. Part A included questions about the distance of walking without fatigue, severity and frequency of equilibration problems, the intensity of pain in the lower limbs while walking, sensation loss and general weakness. Part B was based on the Beck scale in Polish adaptation [8]. To compare the results of both tests first – filled retrospectively for the time of the first approach and second – done on our check-up we used one to ten scale adding negative points from each question.
Case reports
Case 1

M.K., a 50-year-old white woman, first presented in February 1994 with 9-year history of progressive troubles in walking which started after pregnancy and made her resign from work as a shopping assistant. The proband complained of a burning pain in the lower limbs while moving even small distances (500 meters), balance problems and tripping. Neurological examination at that time apart from lower limbs paresis showed weakness in the upper limbs and various degrees of superficial and deep sensation impairment at trunk and lower limbs.
Preliminary diagnosis included sclerosis multiplex, but cerebrospinal fluid examination excluded that suspicion. At this point myelosis funicularis was taken into consideration, but vitamin B12 and folium acid concentrations demonstrated only small variations from the average.
EMG studies in 1994 and 1995 demonstrated a neurogenic process with deficit of sensory and motor fibers and signs of reinnervation.
Ophthalmologic consultation revealed rarefied arteries and pigment regrouping. ECG and EEG showed no appreciable changes, but MRI disclosed mild enlargement of lateral ventricles and signs of spinal atrophy.
Before the genetic studies were performed in Sweden in 1997 the diagnosis remained unclear. As described above hypertrophic, demyelinization processes and microelements deficiency were excluded. In Sweden proband’s nephew started to present symptoms of LD which led to genetic examination of the whole family. It revealed a high degree of T8993C DNA heteroplasmy in proband’s vastus muscle and lymphocyte samples (Table II).

Biopsy and histopathological examination of quadriceps muscle done soon after genetic examinations disclosed mixed neurogenic and metabolic muscle impairment with various fiber size, lipid accumulation and signs of reinnervation [8].
On our examination in 2003 patient complained of stiffness in both lower limbs which made her stay at home and walk only with a support. She admitted that balance problems worsened especially at rest.
These findings were not present or less expressed 9 years ago. EMG revealed markedly increased dennervation changes. QOL test results showed progression of the disease presenting an increased number of negative points checked off by the patient in both parts (Table III).

Case 2
A.K., a 18-year-old woman, was born in 1985 with 10 pts Apgar followed by transient respiratory failure. She started to present slight fatigue and troubles at school in the age of 12 with psychological examination of mild mental deficiency.
Laboratory examinations from that time demonstrated borderline concentration of lactate in blood and muscle histologic studies showed some onset changes in fiber lipid content. EMG disclosed neurogenic type changes, while MRI and ophthalmologic examinations did not disclose any LD specific alterations.
In the anamnesis from 2003 proband complained of the pain in the lower limbs while walking present even after short physical efforts. Symptoms were accompanied by problems with keeping balance, tripping and bruising knees. Needle EMG of the right brachial biceps performed at time of control disclosed myopathy type changes. Genetic studies of the proband are presented in Table II.
In the assessment of quality of life the patient checked off approximately the same number of negative points in 1996 and in 2003 (Table III).
Case 3
M.K., twin sister of the patient presented in case 2, was born with 9 pts Apgar and body mass 2200 g showing signs of dystrophy. She never presented any clinical symptoms of LD. In 1996 she underwent the same examinations as her sister which disclosed paragon able results despite the different clinical phenotype of two sisters. Genetic studies of the proband are presented in Table II.
Because at the time of control in 2003 she did not have any clinical symptoms we decided to limit our investigations to quality of life questionnaire (Table III).

Discussion
Apart from Leigh disease T8993C mutation can be found in other mitochondrial myopathies like NARP (neurogenic ataxia and retinitis pigmentosa) or Leber disease [3, 10].
We excluded the alternate diagnosis because of the lack of eye fundus alterations and absence of the optic nerve atrophy in studied cases.
We suggest that neurological lesions can coexist with muscle impairment which is a reason why both types of electrophysiological abnormalities can be found in LD patients at a different time from the onset. An argument sustaining that theory could be modifications found on muscle histological examinations.
Neurophysiological examinations seem to be very sensitive even in an early state of the disease but they are unspecific and do not present a good prognostic value for LD. The „gold standard” of diagnosis and prognosis are genetic studies though on the other hand they cannot specify the symptoms onset time and the velocity of disease progression. It is important in LD to study muscles and nerves which present most severe symptoms because the results of neurophysiological studies can vary from one to another segment of the patients organism with the variations of heteroplasmy among one or different tissues. It should be emphasized that examinations aimed at other neuromuscular segments in the studied probands could have disclosed more alterations.
The results of EMG examinations were very similar in two sisters in 1996 despite their different clinical state. The similarity of changes can derive from the fact that we studied two heterozygotic twins. There are not any published cases about twins with LD. The psychomotor retardation in case 2 could have been caused by transient neonatal respiratory failure characteristic of LD. The difference in the clinical state among two twin daughters may be also explained with genetic studies. In case 2 heteroplasmy in muscle and blood samples were higher then in case 3. That concentration difference in mutated mtDNA among both sisters might be responsible for the early onset of the disease in one of them and only small abnormalities present in the other which may eventually lead to a fully expressed disease in the future.
Onset of the symptoms after a pregnancy period in case 1 supports the thesis that oxygen demanding stress events with genetic background can all together lead to clinical demonstration or progression of the disease11. For this reason all our patients were advised to limit exercise to a necessary minimum and avoid stress situations. The risk which cannot be mathematically measured. persists for both daughters in case of their pregnancy.

Conclusions
In Leigh disease we must consider to events which are nerve and muscle impairment. LD is a progressive disorder which exacerbates in stress situations such us respiratory failure, pregnancy or infection. Neurophysiological examinations are a sensitive but an unspecific diagnostic method in Leigh disease and correlate well with progression of the disorder, but they do not assess the clinical state of the patient. We introduce the quality of life questionnaires to the LD examinations as a good marker of the clinical state in these patients.

Acknowledgments
We would like to acknowledge: Prof. E Pronicka, MD PhD Head of the Section of Metabolic Disorders of the Department of Pediatrics in the Children’s Memorial Health Institute in Warsaw; M. Rakowicz, MD PhD from Department of Clinical Neurophysiology of the Institute of Psychiatry and Neurology in Warsaw; Prof. K. Rowinska-Marcinska, MD PhD, A. Kostera-Pruszczyk, MD PhD, B. Zakrzewska-Pniewska, MD PhD from the Department of Neurology of the Central Clinical Hospital at the Medical University of Warsaw; prof. K. Wrześniewski, MD PhD Head of the Psychology Department at the Medical University of Warsaw and Z. Tomankiewicz, MD PhD Head of the Section of Neurology at the Specialty Hospital in Miedzylesie.
References
1. Jiang YW, Qin J, Yuan Y, Qi Y, Wu XR. Neuropathologic and clinical features in eight Chinese patients with Leigh disease. J Child Neurol 2002; 17: 450-2.
2. Kisiel B, Małek Ł. Mitochondrial cytopathies: genetic, biochemical and clinical features. Diagnosis and management. New Medicine 2003; 6: 35-40.
3. http://www.neuro.wustl.edu
4. DiMauro S, De Vivo DC. Genetic heterogeneity in Leigh Syndrome. Ann Neurol 1996; 40: 5-7.
5. Jacobs JM, Harding BN, Lake BD, Payan J, Wilson J. Peripheral neuropathy in Leigh disease. Brain 1990; 113: 447-62.
6. Savasta S, Comi GP, Perini MP, Lupi A, Strazzer S, Rognoni F et al. Leigh Disease: Clinical, neuroradiologic, and biochemical study of three new cases with cytochrome c oxidase deficiency. J Child Neurol 2001; 16: 08-13.
7. Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 1996; 39: 343-51.
8. Pużyński S. Depresje. PZWL, Warszawa 1988.
9. Pronicki M, Woźniewicz BM, Kulczycki J, Kaczmarewicz E, Czarnowska E, Szymańska-Dębińska T et al. Muscle morphology in four members of the family with T8993C mitochondrial mutation. Annals of Diagnostic Paediatric Pathology 1997; 1: 117-21.
10. Santorelli FM, Mak SC, Vazquez-Memije E, Shanske S, Kranz-Eble P, Jain KD et al. Clinical heterogenecity associated with the mitochondrial DNA T8993C point mutation. Ped Res 1996; 39: 914-7.
11. Schmiedel J, Jackson S, Schafer J, Reichmann H. Mitochondrial cytopathies. J Neurol 2003; 250: 267-77.







































Copyright: © 2005 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe